Improved Survival After Multimodal Approach with 131I Treatment in Patients with Bone Metastases Secondary to Differentiated Thyroid Cancer.

Background: The objective of this study was to evaluate the overall survival (OS) of radioiodine (131I) treatments alone or combined with non-131I treatments in patients with bone metastases (BM) of differentiated thyroid cancer (DTC). Methods: This was a retrospective study of patients who were evaluated between 2001 and 2018 at MedStar Washington Hospital Center and who had DTC, BM, and at least one 131I treatment after the diagnosis of BM. The OS was analyzed by Kaplan-Meier survival curves and was compared by log-rank test between two groups: patients who received 131I treatments alone and those who received treatments combining 131I with non-131I treatments (CombTx). Non-131I treatments include surgery, radiofrequency ablation, cryotherapy, arterial embolization, external beam radiation, Cyberknife, systemic targeted therapy, and anti-resorptive medication. Results: A total of 77 patients met the above criteria and were followed up to 41 years. Thirty percent (23/77) of patients received 131I treatment alone, and 70% (54/77) received CombTx. For 131I treatment alone, the median survival was 3.9 years, and the 1-, 2-, 3-, 5-, and 10-year OS rates were 86%, 81%, 61%, 35%, and 23%, respectively. For CombTx, the median survival was 7.7 years, and the 1-, 2-, 3-, 5-, and 10-year OS rates were 96%, 92%, 86%, 69%, and 30%, respectively. Patients who had undergone initial 131I therapy within six months post thyroidectomy demonstrated a better median survival after BM diagnosis than those whose initial 131I therapy was six months or more after thyroidectomy (6.5 vs. 0.5 years; p < 0.001). Patients who received external beam radiation therapy demonstrated a better median survival than those who did not (7.8 vs. 4.4 years; p = 0.016). Patients who received denosumab demonstrated a better median survival than those who did not (7.7 vs. 5.2 years; p = 0.03). Patients who were <55 years of age at the initial diagnosis of DTC or at the initial diagnosis of BM had a better median OS than those diagnosed at ≥55 years of age (both p = 0.01). In the multivariate analysis, only age at initial diagnosis of DTC and initial 131I therapy within six months post thyroidectomy, and multiple 131I treatments were independent prognostic factors. Conclusions: In patients with DTC with BM, 131I treatment in combination with one or more non-131I direct and systemic treatments was associated with a significant increase in OS compared with those patients who were treated by 131I treatment alone.

[1]  D. Nostrand Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer , 2017 .

[2]  A. Bockisch,et al.  124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer , 2016, The Journal of Nuclear Medicine.

[3]  H. Tsuchiya,et al.  The impact of complete surgical resection of spinal metastases on the survival of patients with thyroid cancer , 2016, Cancer medicine.

[4]  G. Agarwal,et al.  Long-Term Outcome of Follicular Thyroid Carcinoma in Patients Undergoing Surgical Intervention for Skeletal Metastases , 2016, World Journal of Surgery.

[5]  X. Buy,et al.  Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  S. Takao,et al.  Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma , 2015, Annals of Surgical Oncology.

[7]  Quan-Yong Luo,et al.  Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy. , 2015, Thyroid : official journal of the American Thyroid Association.

[8]  F. Kallel,et al.  Clinical features of bone metastasis for differentiated thyroid carcinoma: A study of 21 patients from a Tunisian center , 2014, Indian journal of endocrinology and metabolism.

[9]  B. Lang,et al.  Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis , 2012, Annals of Surgical Oncology.

[10]  C. Hsieh,et al.  Long‐term outcomes of distant metastasis from differentiated thyroid carcinoma , 2012, Clinical endocrinology.

[11]  Quan-Yong Luo,et al.  Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. , 2011, The Journal of clinical endocrinology and metabolism.

[12]  I. Sugitani,et al.  Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. , 2010, Surgery.

[13]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[14]  C. Harmer,et al.  Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome , 2005, Clinical endocrinology.

[15]  J. Romijn,et al.  Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  D. van Nostrand,et al.  Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. , 2002, Thyroid : official journal of the American Thyroid Association.

[17]  G. Hejblum,et al.  Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  T. Petrich,et al.  Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age , 2001, European Journal of Nuclear Medicine.

[19]  J. Juang,et al.  Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. , 1999, Thyroid : official journal of the American Thyroid Association.

[20]  H. Maxon,et al.  Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.

[21]  S. Dinneen,et al.  Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. , 1995, The Journal of clinical endocrinology and metabolism.

[22]  G. Masarotto,et al.  Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients , 1991, Tumori.

[23]  E. Bergstralh,et al.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.

[24]  B. Caillou,et al.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. , 1986, The Journal of clinical endocrinology and metabolism.

[25]  S. Filetti,et al.  Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience , 2017, Endocrine.

[26]  J. Wexler Bone Metastases from Differentiated Thyroid Carcinoma , 2016 .

[27]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  S. Larson,et al.  Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. , 2000, Thyroid : official journal of the American Thyroid Association.